News > Hetero launches Favivir to treat mild to moderate Covid symptoms

Hetero launches Favivir to treat mild to moderate Covid symptoms

Hetero, one of India's leading generic pharmaceutical companies and the world's largest producer of antiretroviral drugs, on Wednesday announced the launch of generic Favipiravir in India under the brand name Favivir.

Favivir improves treatment accessibility to a significant amount of COVID-19 patient population, which usually sustains mild to moderate symptoms. It is the second drug developed by Hetero after Covifor (Remdesivir) used in the treatment of COVID. It is an oral antiviral medication with positive clinical outcomes.